We focus primarily on ambitious life sciences projects in three domains:
- Medical devices
- Industrial biotechnology
In all those domains we invest in game-changing technologies, on projects able to revolutionize their respective industries and address tomorrow’s challenges. Priority is given to projects which have secured strong intellectual property and which combine entrepreneurial track-record with pharmaceutical or industrial experience.
We invest in start-ups, typically originated in the academic world, as well as spin-offs, which are new companies formed around later stage assets that had been developed in and spun-off from larger corporations. This is particularly true in the field of biopharmaceuticals where we have generated a unique spin-off track record.